Literature DB >> 21185706

Prevention of cancer by prophylactic human papillomavirus vaccines.

Kihyuck Kwak1, Anna Yemelyanova, Richard B S Roden.   

Abstract

Oncogenic human papillomaviruses (HPVs) are exclusively mucosal pathogens that are noncytopathic and the basal epithelial cells harboring and maintaining an infection do not produce either capsid antigen or virus. The efficacy of the licensed L1 virus-like particle (VLP) vaccines has encouraged development of several second generation vaccines aimed at expanding the coverage to all oncogenic HPV types and reducing barriers to global implementation. Currently there is no defined immune correlate of protection that can be used to determine if an individual patient is protected and for the evaluation of these second generation vaccines. Surprisingly, passive transfer of neutralizing serum antibody is protective in animal models. Recent studies suggest how neutralizing antibody mediates immunity against mucosal HPV and the possible impact of memory B cells.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21185706      PMCID： PMC3070794          DOI： 10.1016/j.coi.2010.11.009

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN： 0952-7915            Impact factor:   7.486


  52 in total

1.  Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection.

Authors:  Rebecca M Richards; Douglas R Lowy; John T Schiller; Patricia M Day
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-23       Impact factor: 11.205

2.  Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective.

Authors:  T Yamada; M M Manos; J Peto; C E Greer; N Munoz; F X Bosch; C M Wheeler
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

3.  In vivo mechanisms of vaccine-induced protection against HPV infection.

Authors:  Patricia M Day; Rhonda C Kines; Cynthia D Thompson; Subhashini Jagu; Richard B Roden; Douglas R Lowy; John T Schiller
Journal:  Cell Host Microbe       Date:  2010-09-16       Impact factor: 21.023

4.  Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16.

Authors:  X S Chen; R L Garcea; I Goldberg; G Casini; S C Harrison
Journal:  Mol Cell       Date:  2000-03       Impact factor: 17.970

5.  In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype.

Authors:  R B Roden; H L Greenstone; R Kirnbauer; F P Booy; J Jessie; D R Lowy; J T Schiller
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

6.  Nasal vaccination with attenuated Salmonella typhimurium strains expressing the Hepatitis B nucleocapsid: dose response analysis.

Authors:  D Nardelli-Haefliger; J Benyacoub; R Lemoine; S Hopkins-Donaldson; A Potts; F Hartman; J P Kraehenbuhl; P De Grandi
Journal:  Vaccine       Date:  2001-04-06       Impact factor: 3.641

Review 7.  Antiviral antibody responses: the two extremes of a wide spectrum.

Authors:  Lars Hangartner; Rolf M Zinkernagel; Hans Hengartner
Journal:  Nat Rev Immunol       Date:  2006-03       Impact factor: 53.106

8.  Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles.

Authors:  Denise Nardelli-Haefliger; Daniel Wirthner; John T Schiller; Douglas R Lowy; Allan Hildesheim; Françoise Ponci; Pierre De Grandi
Journal:  J Natl Cancer Inst       Date:  2003-08-06       Impact factor: 13.506

9.  Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.

Authors:  Subhashini Jagu; Balasubramanyam Karanam; Ratish Gambhira; Sudha V Chivukula; Revathi J Chaganti; Douglas R Lowy; John T Schiller; Richard B S Roden
Journal:  J Natl Cancer Inst       Date:  2009-05-26       Impact factor: 13.506

10.  DNA-vaccination via tattooing induces stronger humoral and cellular immune responses than intramuscular delivery supported by molecular adjuvants.

Authors:  Dana Pokorna; Ivonne Rubio; Martin Müller
Journal:  Genet Vaccines Ther       Date:  2008-02-07
View more
  15 in total

Review 1.  Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling.

Authors:  Helen Y Wang; Rong-Fu Wang
Journal:  Adv Immunol       Date:  2012       Impact factor: 3.543

2.  Down-regulation of Frizzled-7 expression inhibits migration, invasion, and epithelial-mesenchymal transition of cervical cancer cell lines.

Authors:  Boya Deng; Siyang Zhang; Yuan Miao; Yi Zhang; Fang Wen; Kejun Guo
Journal:  Med Oncol       Date:  2015-03-05       Impact factor: 3.064

Review 3.  New approaches to prophylactic human papillomavirus vaccines for cervical cancer prevention.

Authors:  Elizabeth D Gersch; Lutz Gissmann; Robert L Garcea
Journal:  Antivir Ther       Date:  2011-11-07

Review 4.  Human papillomaviruses-related cancers. Presence and prevention strategies in the Middle east and north African regions.

Authors:  Ala-Eddin Al Moustafa; Rana Al-Awadhi; Nabiha Missaoui; Ishag Adam; Raika Durusoy; Lina Ghabreau; Nizar Akil; Hussain Gadelkarim Ahmed; Amber Yasmeen; Ghazi Alsbeih
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

5.  Immunogenicity and tolerability to human papillomavirus-like particle vaccine in girls and young women with inflammatory bowel disease.

Authors:  Denise L Jacobson; Athos Bousvaros; Lori Ashworth; Rebecca Carey; Lydia A Shrier; Sandra K Burchett; Harmony Renna; Ying Lu
Journal:  Inflamm Bowel Dis       Date:  2013-06       Impact factor: 5.325

6.  Efficient production of HIV-1 virus-like particles from a mammalian expression vector requires the N-terminal capsid domain.

Authors:  Pascal Jalaguier; Karine Turcotte; Alexis Danylo; Réjean Cantin; Michel J Tremblay
Journal:  PLoS One       Date:  2011-11-30       Impact factor: 3.240

7.  Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity.

Authors:  Qinjian Zhao; Yorgo Modis; Katrina High; Victoria Towne; Yuan Meng; Yang Wang; Jaime Alexandroff; Martha Brown; Bridget Carragher; Clinton S Potter; Dicky Abraham; Dave Wohlpart; Mike Kosinski; Mike W Washabaugh; Robert D Sitrin
Journal:  Virol J       Date:  2012-02-22       Impact factor: 4.099

8.  A chimeric EBV gp350/220-based VLP replicates the virion B-cell attachment mechanism and elicits long-lasting neutralizing antibodies in mice.

Authors:  Javier Gordon Ogembo; Matthew R Muraswki; Lori W McGinnes; Agapi Parcharidou; Rujapak Sutiwisesak; Timelia Tison; Juan Avendano; Deep Agnani; Robert W Finberg; Trudy G Morrison; Joyce D Fingeroth
Journal:  J Transl Med       Date:  2015-02-06       Impact factor: 5.531

Review 9.  Ever closer to a prophylactic vaccine for HCV.

Authors:  Leo Swadling; Paul Klenerman; Eleanor Barnes
Journal:  Expert Opin Biol Ther       Date:  2013-05-07       Impact factor: 4.388

10.  Attenuated Recombinant Influenza A Virus Expressing HPV16 E6 and E7 as a Novel Therapeutic Vaccine Approach.

Authors:  Christoph Jindra; Bettina Huber; Saeed Shafti-Keramat; Markus Wolschek; Boris Ferko; Thomas Muster; Sabine Brandt; Reinhard Kirnbauer
Journal:  PLoS One       Date:  2015-09-18       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.